Cargando…

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane

MicroRNAs (miRNAs) have been reported to regulate the development of chemoresistance in many tumors. Stathmin 1 (STMN1) is a microtubule-depolymerizing molecule, involved in chemo-response; however, the mechanism of its regulation is unknown. Herein, the immunohistochemical study indicated significa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Mohamed Kamel, Watari, Hidemichi, Mitamura, Takashi, Mohamed, Zainab, EL-khamisy, Sherif F., Ohba, Yusuke, Sakuragi, Noriaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394135/ https://www.ncbi.nlm.nih.gov/pubmed/25897432

Ejemplares similares

miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2
por: Mohamed, Zeinab, et al.
Publicado: (2018)

Apoptosis and Molecular Targeting Therapy in Cancer
por: Hassan, Mohamed, et al.
Publicado: (2014)

microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET
por: Mitamura, T, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection
por: Hassan, Mohamed K., et al.
Publicado: (2014)

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
por: Hassan, Mohamed K, et al.
Publicado: (2011)

Correction: microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments
por: Mitamura, Takashi, et al.
Publicado: (2014)

Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer
por: Hassan, Mohamed K., et al.
Publicado: (2021)

MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells
por: Dong, Peixin, et al.
Publicado: (2016)

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer
por: Dong, Peixin, et al.
Publicado: (2018)

Correction: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer
por: Dong, Peixin, et al.
Publicado: (2019)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy
por: Kato, Tatsuya, et al.
Publicado: (2013)

Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Multivariate survival analysis of the patients with recurrent endometrial cancer
por: Odagiri, Tetsuji, et al.
Publicado: (2011)

The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer
por: Dong, Peixin, et al.
Publicado: (2014)

Emerging Therapeutic Biomarkers in Endometrial Cancer
por: Dong, Peixin, et al.
Publicado: (2013)

MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1
por: Dong, Peixin, et al.
Publicado: (2011)

MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells
por: Konno, Yosuke, et al.
Publicado: (2014)

Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression
por: Dong, Peixin, et al.
Publicado: (2016)

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study
por: Zhai, Tianyue, et al.
Publicado: (2023)

EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
por: Ihira, Kei, et al.
Publicado: (2017)

Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer
por: Mitamura, Takashi, et al.
Publicado: (2022)

Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients
por: Kuang, Xia-Ying, et al.
Publicado: (2015)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer
por: YING, LISHA, et al.
Publicado: (2013)

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
por: Sonego, Maura, et al.
Publicado: (2014)

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
por: Sonego, Maura, et al.
Publicado: (2013)

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)
por: Ohnishi, Shunsuke, et al.
Publicado: (2017)

MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1
por: Wang, Rui, et al.
Publicado: (2012)

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
por: Dong, Peixin, et al.
Publicado: (2015)

Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors
por: Brattsand, G
Publicado: (2000)

Op18/Stathmin Mediates Multiple Region-Specific Tubulin and Microtubule-Regulating Activities
por: Larsson, Niklas, et al.
Publicado: (1999)

Siva 1 inhibits proliferation, migration and invasion by phosphorylating Stathmin in ovarian cancer cells
por: Ma, Yifei, et al.
Publicado: (2017)

Stathmin Is Dispensable for Tumor Onset in Mice
por: D’Andrea, Sara, et al.
Publicado: (2012)

Stathmin 1 in normal and malignant hematopoiesis
por: Machado-Neto, João Agostinho, et al.
Publicado: (2014)

Stathmin drives virus-induced metastasis
por: Whitehouse, Adrian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tpdg1hmadl70d54bfk8r8gjqcf